Expanded BTK Inhibitor Research Directs the Evolution of Pirtobrutinib Use in CLL: With Andrew Lipsky, MD

Welcome to OncLive On Air®! I’m your host today, Courtney Flaherty.

OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, Andrew Lipsky, MD, reviewed recent updates with BTK inhibitors in the chronic lymphocytic leukemia (CLL) treatment paradigm, including the clinical significance of the December 2025 FDA approval of pirtobrutinib (Jaypirca) in relapsed/refractory CLL and its effect on sequencing decisions for this disease. Dr Lipsky is an assistant professor of medicine at the Columbia University Medical Center in New York, New York.

In the exclusive interview, Dr Lipsky expanded on the positioning of this agent within the evolving CLL treatment paradigm and patient characteristics that may inform its use in practice; key efficacy and safety findings from a pooled analysis of the phase 3 BRUIN CLL-321 (NCT04666038) and phase 1/2 BRUIN LOXO-BTK-18001 (NCT03740529) studies presented during the 2025 ASH Annual Meeting; and the evolving role of BTK inhibitors as a whole in CLL management.

_____

That’s all we have for today! Thank you for listening to this episode of OncLive On Air. Check back throughout the week for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air.

This content is a production of OncLive; this OncLive On Air podcast episode is supported by funding, however, content is produced and independently developed by OncLive.